JOHNSON & JOHNSON (JNJ) Form 8-K — Oct 13, 2026
Johnson & Johnson reported Q3 2026 sales of $25.4 billion, up 5.9% year over year, with Innovative Medicine growing 7.7% and MedTech up 2.5%. GAAP EPS fell to $0.09 (net earnings $210M, down 95.9%) due to a one-time special charge for the proposed talc litigation resolution plus the Firefly Bio acquisition and Sail Biomedicines collaboration. The company raised full-year 2026 guidance, lifting adjusted EPS by $0.06 to $11.10 at the midpoint and projecting estimated reported sales of $101.2 billion (+7.4%). Adjusted EPS of $2.59 was down 7.5% year over year, reflecting M&A impacts.
Key figures
- Eps
- 0.09
- Revenue
- 25399000000
- Guidance
- 2026 estimated reported sales $101.0B-$101.4B ($101.2B midpoint, +7.4%); adjusted EPS raised $0.06 to $11.05-$11.15 ($11.10 midpoint, +2.9%)
- Net Income
- 210000000
- Revenue Yoy
- 5.9%
- Medtech sales
- $8,642M (+2.5%)
- Free cash flow
- ~$15,100M
- Adjusted eps q3
- $2.59 (vs $2.80 prior year, -7.5%)
- Nine month sales
- $74,771M (+7.4%)
- Iprd impairments q3
- $339M
- Adjusted net earnings
- $6,339M
- Reported sales growth q3
- 5.9%
- Innovative medicine sales
- $16,757M (+7.7%)
- Operational sales growth q3
- 6.0%
- Litigation related special items q3
- $5,519M
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.